Phosphorex
Phosphorex is a private Hopkinton, Massachusetts-based CDMO specializing in lipid nanoparticles, polymeric nanoparticles, and polymeric microspheres for advanced therapeutic delivery to biotech and pharma clients developing nucleic acid, gene, vaccine, and sustained-release drugs.
- Company typePrivate
- Founded2005
- HeadquartersHopkinton, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Phosphorex does
Phosphorex serves biotech and biopharmaceutical customers developing nucleic acid medicines (mRNA, siRNA, pDNA), gene and RNA therapies, vaccines, oncology therapeutics, and long-acting injectables that require specialized formulation, analytical, and CMC support. Revenue is generated through project-based, custom-quoted CDMO contracts spanning feasibility through preclinical development, with active investment in cGMP manufacturing capacity intended to extend the offering into clinical-stage production. The company is backed by Ampersand Capital Partners as primary financial sponsor and by NOF Corporation as a strategic minority shareholder and technology partner. Go-to-market is enterprise-direct, relying on industry conference presence (ASGCT, BIO International, LNP Formulation & Process Development Summit), educational webinars, technical content, and the LNP Alliance ecosystem to reach R&D and CMC decision-makers at client biotech and pharma organizations.
Phosphorex firmographics
Firmographics- Name
- Phosphorex
- Legal name
- Phosphorex LLC
- Website
- https://phosphorex.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Phosphorex is a private Hopkinton, Massachusetts-based CDMO specializing in lipid nanoparticles, polymeric nanoparticles, and polymeric microspheres for advanced therapeutic delivery to biotech and pharma clients developing nucleic acid, gene, vaccine, and sustained-release drugs.
- Ownership category
- akta.pro rank
Phosphorex industry classification
Industry- Product category
- Pharmaceutical Contract Development and Manufacturing (CDMO)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
Keywords
Where Phosphorex is headquartered
LocationHeadquarters
- HQ city
- Hopkinton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Phosphorex business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain
Revenue model
- Contract Development and Manufacturing Services: Phosphorex generates revenue as a CDMO providing drug delivery formulation, process development, analytical services, and tech transfer support to biotech and pharma companies developing advanced therapeutics. Services span from early feasibility through clinical translation, with revenue generated through project-based contracts and potentially recurring engagement as programs advance through development phases.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Phosphorex product offering
Product offeringCore offering
Phosphorex is a contract development and manufacturing organization (CDMO) providing drug delivery formulation, process development, analytical services, and tech transfer for advanced therapeutics. Its core offerings are built around three particle-based drug delivery platforms — lipid nanoparticles (LNPs), polymeric nanoparticles (PNPs), and polymeric microspheres — combined within the integrated Phosphorex Drug Delivery Engine that advances programs from early feasibility through preclinical development and GMP manufacturing readiness.
Product overview
Phosphorex is a drug delivery-focused CDMO offering an integrated platform of particle-based drug delivery solutions organized around the Phosphorex Drug Delivery Engine. The core platform encompasses three main drug delivery technologies: Lipid Nanoparticles (LNPs), Polymeric Nanoparticles (PNPs), and Polymeric Microspheres, each addressing different therapeutic delivery needs from nucleic acid delivery to sustained-release applications. The Drug Delivery Engine itself consists of four interconnected modules: Formulation Optimization, Process Design & CMC, Analytical Expertise, and Tech Transfer/Process Optimization. These are complemented by Licensable LNP Development Services (as NOF Corporation's North American LNP Center of Excellence) and the LNP Alliance partnership for integrated end-to-end development. The company supports diverse therapeutic modalities including nucleic acid delivery, gene and RNA medicines, vaccines, oncology, and long-acting injectables.
Differentiator
Problem solved
Functional benefit
Products and services
- Phosphorex Drug Delivery Engine Integrated drug delivery development platform that combines formulation optimization, process design and CMC, analytical expertise, and tech transfer capabilities to advance nanoparticle-based therapeutics from concept to clinic. Available to biotech and pharma clients as the overarching CDMO engagement.
- Lipid Nanoparticles (LNPs) Next-generation lipid nanoparticle platform CDMO offering for delivering nucleic acids to extra-hepatic tissues with cell-specific targeting capabilities. Serves biotech and pharma developers of mRNA, siRNA, pDNA, gene editing, and vaccine programs.
- Polymeric Nanoparticles (PNPs) Biodegradable polymer-based nanoparticle CDMO offering using polyethylene glycol (PEG) copolymers for precise targeting and payload protection from degradation. Available to developers needing targeted delivery of nucleic acids, peptides, proteins, and small molecules.
- Polymeric Microspheres Sustained-release microsphere CDMO offering using biodegradable polymers for encapsulating small molecules, peptides, and proteins to prolong drug exposure and reduce dosing frequency. Supports long-acting injectable and sustained-release therapeutic programs.
- Licensable LNP Development Services Center-of-excellence offering providing evaluation of LNP candidates from NOF Corporation's proprietary, licensable ionizable lipid libraries with high-throughput screening, candidate nomination, and in vivo validation. Designed for biotech and pharma clients seeking licensable LNP technology.
- LNP Alliance Strategic partnership platform offering an integrated end-to-end lipid nanoparticle development offering combining proprietary lipids, formulation and process expertise, advanced analytics, imaging, and preclinical evaluation to accelerate next-generation therapeutics to the clinic.
Companies that use Phosphorex
Customer profileSegments1 record
Ideal customer profiles1 record
Phosphorex technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Phosphorex partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- LNP Alliance (NeoSome Life Sciences, NanoImaging Services, Envol Biomedical)coreThe LNP Alliance brings together Phosphorex, NOF CORPORATION, NeoSome Life Sciences, NanoImaging Services, and Envol Biomedical to provide an integrated, end-to-end platform for lipid nanoparticle development. The alliance combines proprietary lipids, formulation and process expertise, advanced analytics, imaging, and preclinical evaluation to accelerate next-generation therapeutics to the clinic. Each member contributes specialized expertise across the LNP development lifecycle.
- NeoSome Life SciencescoreInnovative preclinical CRO providing comprehensive in vitro and in vivo services to support drug discovery and development across various therapeutic areas. Member of the LNP Alliance providing biodistribution, efficacy, and toxicology evaluations in multiple animal models including Non-Human Primates.
- NanoImaging ServicescoreLeader in cryo-electron microscopy (cryo-EM) and nanoparticle characterization, ensuring the highest quality and integrity for LNP-based therapeutics. Provides Cryo-TEM imaging for nanoparticle characterization as part of the LNP Alliance ecosystem.
- Envol BiomedicalcoreLeading non-clinical laboratory offering pharmacology and toxicology capabilities focused on Non-Human Primates. Member of the LNP Alliance providing in vivo efficacy and safety evaluation services.
- NOF AMERICA CORPORATIONcoreCollaboration to supply Phosphorex's global clients with NOF's COATSOME SS Series proprietary ionizable lipids. The combination of NOF's lipid technologies and Phosphorex's experience in developing and scaling LNP-based drug delivery solutions delivers faster, more cost-effective, and reproducible outcomes for customers. This integrated approach provides a well-characterized platform for customers developing LNP-based therapies.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
Phosphorex competitors and assessment
Company assessmentDirect peers
- BioVectra: BioVectra (acquired by Agilent) is a CDMO specializing in complex small molecules, biologics, and nucleic acid manufacturing including plasmid DNA and LNP components; it serves a comparable biotech CDMO customer base for advanced therapeutics.
- Genevant Sciences: Genevant is an LNP delivery technology company that licenses lipid nanoparticle platforms and provides formulation services to nucleic acid developers; it directly overlaps with Phosphorex's LNP formulation and licensing business model.
- Precision NanoSystems (Cytiva): Precision NanoSystems, acquired by Cytiva/Danaher in 2023, is a direct competitor offering LNP formulation instruments (NanoAssemblr), lipids, and CDMO services for nucleic acid delivery — directly competing with Phosphorex's LNP-focused CDMO offering for biotech and pharma clients.
- Aldevron: Aldevron (acquired by Danaher) is a CDMO providing nucleic acids, proteins, and mRNA manufacturing services to gene therapy and vaccine developers; it overlaps with Phosphorex on the nucleic acid therapeutic development customer base.
- Ascendia Pharma: Ascendia Pharma is a specialty CDMO focused on pre-formulation, formulation, and nano-emulsion/nanoparticle drug delivery for poorly soluble drugs and complex injectables, providing comparable nano-formulation CDMO services to biotech clients.
- TriLink BioTechnologies: TriLink (a Maravai LifeSciences company) manufactures mRNA, oligonucleotides, and nucleic acids for therapeutic and vaccine developers; it serves the same biotech customer base as Phosphorex and offers adjacent CDMO services in nucleic acid-based therapeutics.
- Acuitas Therapeutics: Acuitas is an LNP technology specialist whose ionizable lipids underpin Pfizer-BioNTech's Comirnaty vaccine; it develops LNP formulations for partners and is a direct competitor in the nucleic acid delivery CDMO and licensing space where Phosphorex operates.
Broad incumbents
- Lonza: Lonza is a leading global CDMO with significant nucleic acid, LNP, and biologics manufacturing capacity; its Mammalian, Microbial, and mRNA services compete with Phosphorex for advanced therapeutics development contracts at the upper end of the market.
- CordenPharma: CordenPharma is a full-service CDMO with growing lipid nanoparticle and nucleic acid manufacturing capabilities (including via the Moderna alliance); it competes broadly with Phosphorex for nucleic acid CDMO contracts from larger pharma and biotech clients.
- Evonik Health Care: Evonik offers lipid excipients, polymeric microspheres (RESOMER), and CDMO services for parenteral and complex injectable formulations; its RESOMER polymer and lipid portfolio competes directly with Phosphorex's polymeric microsphere and LNP offerings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights5 records
Customer concentration
Phosphorex social profiles
Digital presencePhosphorex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phosphorex leadership team
Management profileNumber of profiles
Profiles12 records
Phosphorex funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phosphorex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phosphorex
What does Phosphorex do?
Phosphorex is a contract development and manufacturing organization (CDMO) providing drug delivery formulation, process development, analytical services, and tech transfer for advanced therapeutics. Its core offerings are built around three particle-based drug delivery platforms — lipid nanoparticles (LNPs), polymeric nanoparticles (PNPs), and polymeric microspheres — combined within the integrated Phosphorex Drug Delivery Engine that advances programs from early feasibility through preclinical development and GMP manufacturing readiness.
Is Phosphorex a public or private company?
Phosphorex is a private company. It is classified as private equity controlled and is currently operating.
When was Phosphorex founded?
Phosphorex was founded in 2005. It employs 1 to 10 people.
Where is Phosphorex based?
Phosphorex is headquartered in Hopkinton, United States, in the North America region.
How does Phosphorex make money?
One revenue line is on record: contract Development and Manufacturing Services.
Who are Phosphorex's main competitors?
Direct peers on record are BioVectra, Genevant Sciences, Precision NanoSystems (Cytiva), Aldevron, Ascendia Pharma, TriLink BioTechnologies and Acuitas Therapeutics. Broad incumbents are Lonza, CordenPharma and Evonik Health Care.
Does Phosphorex have an API?
No public API is recorded for Phosphorex.
What industry is Phosphorex in?
Phosphorex's product category is Pharmaceutical Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO, with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 3254 and its SIC code is 2834.